It is the disease that killed more than 8 million people in 2012 and diagnoses 14 million people each year. It is available in many forms and there is still no cure.
Part of the problem in finding a cure is that, although scientists thought they knew the effects of cancer, they did not understand this insidious disease until the last decade. Cancer is much more complex than expected.
But a company believes it could have a solution. Propanc Health Group Corporation (OTCB: PPCH) focuses on the development of therapies for cancer patients with solid tumors such as pancreatic, ovarian and colorectal cancers.
Until recently, the company had filed four patent applications for its main product, PRP, a proenzyme, an anti-cancer drug designed to eradicate cancer stem cells and save normal stem cells at the same time. Now, the company has added two more to its portfolio.
“I do not doubt that the PRP represents a new class of drugs with significant potential [because] if we confirm the effectiveness of PRP in various cancers, we have also demonstrated a synergistic response between the two proenzymes of most lines Cancer cells, “says Dr. Julian Kenyon, scientific director of propane gas. “We also found that several combinations of both proenzymes have been shown to be effective in some cancers.”
Propanc recently met with the Medicines and Health Products Regulatory Authority (MHRA) to discuss preclinical and formal clinical development of PRP. In addition, the Company intends to shortly apply for Orphan Drug Designation for Pancreatic and Ovarian Cancer in the United States and Europe.
With five new patents, the biotech company is attracting the attention of investors. In March 2016, Propanc received more than $ 1 million from an institutional investor to quickly track its preclinical activity, for a total of approximately $ 3.6 million.
According to Global Analyst Reports, the global market for pancreatic, ovarian and colon cancers is expected to reach more than $ 12 billion by 2020.Next Post